Completed PHASE1 INTERVENTIONAL 2-arm NCT02493283

Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration

Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses

Sponsor: University Medicine Greifswald

Conditions Linear IgA Bullous Dermatosis Methemoglobinemia

Interventions Dapsone multiple dose Dapsone single dose Met-Hb leucocytes

Updated 6 times since 2017 Last updated: Jul 6, 2015 Started: Sep 30, 2011 Primary completion: Jun 30, 2012 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Linear IgA Bullous Dermatosis and Methemoglobinemia, this trial is completed. The trial is conducted by University Medicine Greifswald and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Medicine Greifswald

Data source: University Medicine Greifswald

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Greifswald, Germany